Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter
Eli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker
By TOM MURPHY
Published - Aug 08, 2024, 02:34 PM ET
Last Updated - Aug 08, 2024, 02:34 PM EDT
INDIANAPOLIS (AP) — Eli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Lilly also hiked its forecast for the year well beyond Wall Street expectations as newer drugs like Zepbound built momentum.
The company’s shares soared Thursday after Lilly detailed its quarterly results.
Mounjaro sales more than tripled in the quarter to nearly $3.1 billion. Zepbound, which is made from the same molecule, brought in $1.2 billion two quarters after regulators approved the drug.
